VPS34 inhibitor SB02024 activates cGAS-STING signaling and sensitizes tumors to STING agonist

Yasmin Yu, Muhammad Z. Noman, Santiago Parpal, Simone C. Kleinendorst, Kristine B. Saether, Andrey Alexeyenko, Jenny Viklund, Martin Andersson, Jessica Martinsson, Katja P. Tamm, Angelo De Milito, Bassam Janji

Research output: Contribution to journalMeeting Abstractpeer-review

Abstract

Novel approaches to reduce tumor immunosuppression and improve responses to anti-cancer immunotherapies based on immune-checkpoint inhibitors are needed. Emerging evidence demonstrates that autophagy inhibition enhances anti-tumor immunity by tumor cell-intrinsic and extrinsic mechanisms. Recently, we reported that pharmacological inhibition of VPS34 (PIK3C3), a lipid kinase regulating autophagy initiation, decreases tumor growth and improve the efficacy of anti-PD-1/PD-L1 therapy in melanoma and colorectal cancer mouse models. This effect was dependent on increasing T and NK cell infiltration as well as the expression of CCL5 and CXCL10 chemokines in the tumor microenvironment. Here, we explored the signaling mechanisms underlying the chemokine release following treatment with VPS34 inhibitor SB02024. We found that both pharmacological and RNAi-mediated inhibition of VPS34 activated a cGAS-STING-dependent type I interferon response in renal cell carcinoma (RCC) and melanoma cell lines. Furthermore, combination treatment of VPS34 inhibitor SB02024 with STING agonist ADU-S100 or cGAMP increased the mRNA expression and release of proinflammatory cytokines in human and murine RCC and melanoma cancer cell lines. Oral administration of SB02024 in combination with intratumoral injections of ADU-S100 significantly decreased tumor growth and weight and improved mice survival of B16-F10 tumor-bearing mice. Taken together, our data demonstrates that targeting of VPS34 results in a cGAS/STING-mediated increase of pro-inflammatory cytokine secretion and synergizes with a STING agonist. We believe that systemic VPS34 inhibition using SB02024 would be of major interest in combination or as an alternative to STING agonists to improve anti-tumor immune responses.Citation Format: Yasmin Yu, Muhammad Z. Noman, Santiago Parpal, Simone C. Kleinendorst, Kristine B. Saether, Andrey Alexeyenko, Jenny Viklund, Martin Andersson, Jessica Martinsson, Katja P. Tamm, Angelo De Milito, Bassam Janji. VPS34 inhibitor SB02024 activates cGAS-STING signaling and sensitizes tumors to STING agonist [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12Suppl):Abstract nr 2116.
Original languageUndefined/Unknown
Article number2116
Pages (from-to)2116-2116
Number of pages1
JournalCancer Research
Volume82
Issue number12_Supplement
DOIs
Publication statusPublished - 15 Jun 2022
EventAnnual Meeting of the American Association for Cancer Research (AACR) 2022 - Philadelphia, United States
Duration: 8 Apr 202213 Apr 2022

Cite this